Literature DB >> 31772965

Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma.

Emma Holliday1, Onita Bhattasali2, Merrill S Kies3, Ehab Hanna4, Adam S Garden1, David I Rosenthal1, William H Morrison1, G Brandon Gunn1, Jack Phan1, X Ronald Zhu5, Xiaodong Zhang5, Steven J Frank1.   

Abstract

PURPOSE: Postoperative radiation therapy can improve control for adenoid cystic carcinoma (ACC) of the head and neck; however, delivering adequate dose to the tumor bed must be balanced with limiting dose to nearby critical organs. Intensity-modulated proton therapy (IMPT) may help improve the therapeutic ratio, though concerns exist regarding tissue heterogeneity and other sources of uncertainty in several head and neck subsites. We report control and toxicity outcomes for patients with ACC of the head and neck treated at a single institution with postoperative IMPT and robust planning and analysis. PATIENTS AND METHODS: Sixteen patients with head and neck ACC treated with postoperative IMPT were identified. Intensity-modulated proton therapy was delivered by using multifield optimization. Robust planning and analysis were performed. The median dose was 60 (range, 60 to 70) Gy (RBE) (Gy [relative biological effectiveness]). Adjuvant IMPT was given with (N = 12) or without (N = 4) platinum-based chemotherapy. Tumor control outcomes were recorded from the medical record, and acute and chronic toxicities were graded weekly during treatment and upon follow-up per Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4).
RESULTS: Median follow-up is 24.9 (range, 9.2 to 40.2) months. One patient developed local and distant recurrence and subsequently died. The remaining 15 patients are alive without evidence of disease. Four patients experienced acute grade 3 toxicities: dermatitis (N = 3) and oral mucositis (N = 1). One patient developed a chronic grade 4 optic nerve disorder. There were no grade 5 toxicities.
CONCLUSIONS: Intensity-modulated proton therapy is a feasible option for patients with ACC of the head and neck in the postoperative setting. Robust treatment planning and plan analysis can be performed such that uncertainties and tissue heterogeneities do not appear to limit safe and effective IMPT delivery. Safety and efficacy appear comparable to those of other types of radiation therapy, but further follow-up of clinical outcomes is needed. © Copyright 2016 International Journal of Particle Therapy.

Entities:  

Keywords:  adenoid cystic carcinoma; head and neck neoplasms; intensity-modulated proton therapy; proton radiotherapy; robust planning

Year:  2016        PMID: 31772965      PMCID: PMC6871643          DOI: 10.14338/IJPT-15-00032.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  34 in total

1.  Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck.

Authors:  William M Mendenhall; Christopher G Morris; Robert J Amdur; John W Werning; Russell W Hinerman; Douglas B Villaret
Journal:  Head Neck       Date:  2004-02       Impact factor: 3.147

2.  The M. D. Anderson proton therapy system.

Authors:  Alfred Smith; Michael Gillin; Martin Bues; X Ronald Zhu; Kazumichi Suzuki; Radhe Mohan; Shiao Woo; Andrew Lee; Ritsko Komaki; James Cox; Kazuo Hiramoto; Hiroshi Akiyama; Takayuki Ishida; Toshie Sasaki; Koji Matsuda
Journal:  Med Phys       Date:  2009-09       Impact factor: 4.071

3.  Proton therapy for head and neck adenoid cystic carcinoma: initial clinical outcomes.

Authors:  Okechukwu R Linton; Michael G Moore; Joseph S Brigance; Don-John Summerlin; Mark W McDonald
Journal:  Head Neck       Date:  2015-01       Impact factor: 3.147

4.  PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization.

Authors:  Wei Liu; Steven J Frank; Xiaoqiang Li; Yupeng Li; Ron X Zhu; Radhe Mohan
Journal:  Med Phys       Date:  2013-02       Impact factor: 4.071

5.  Temporal lobe toxicity analysis after proton radiation therapy for skull base tumors.

Authors:  Berrin Pehlivan; Carmen Ares; Antony J Lomax; Otto Stadelmann; Gudrun Goitein; Beate Timmermann; Ralf A Schneider; Eugen B Hug
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-18       Impact factor: 7.038

6.  A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours.

Authors:  L Cozzi; A Fogliata; A Lomax; A Bolsi
Journal:  Radiother Oncol       Date:  2001-12       Impact factor: 6.280

7.  Clinicopathological features of salivary and non-salivary adenoid cystic carcinomas.

Authors:  Yu-Chin Lin; Ko-Chin Chen; Ching-Hung Lin; Kuan-Ting Kuo; Jeng-Yuh Ko; Ruey-Long Hong
Journal:  Int J Oral Maxillofac Surg       Date:  2012-01-09       Impact factor: 2.789

Review 8.  Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: long-term outcomes, QoL assessment and review of the literature.

Authors:  Abrahim Al-Mamgani; Peter van Rooij; Aniel Sewnaik; Lisa Tans; Jose A U Hardillo
Journal:  Oral Oncol       Date:  2011-11-16       Impact factor: 5.337

9.  Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers.

Authors:  Wei Liu; Steven J Frank; Xiaoqiang Li; Yupeng Li; Peter C Park; Lei Dong; X Ronald Zhu; Radhe Mohan
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

10.  Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy.

Authors:  YingJie Zheng; Fei Han; WeiWei Xiao; YanQun Xiang; LiXia Lu; XiaoWu Deng; NianJi Cui; Chong Zhao
Journal:  Radiat Oncol       Date:  2015-01-13       Impact factor: 3.481

View more
  4 in total

Review 1.  National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States.

Authors:  Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

Review 2.  Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges.

Authors:  Sandra Nuyts; Heleen Bollen; Sweet Ping Ng; June Corry; Avraham Eisbruch; William M Mendenhall; Robert Smee; Primoz Strojan; Wai Tong Ng; Alfio Ferlito
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

3.  Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience.

Authors:  G Brandon Gunn; Adam S Garden; Rong Ye; Noveen Ausat; Kristina R Dahlstrom; William H Morrison; C David Fuller; Jack Phan; Jay P Reddy; Shalin J Shah; Lauren L Mayo; Stephen G Chun; Gregory M Chronowski; Amy C Moreno; Jeffery N Myers; Ehab Y Hanna; Bita Esmaeli; Maura L Gillison; Renata Ferrarotto; Katherine A Hutcheson; Mark S Chambers; Lawrence E Ginsberg; Adel K El-Naggar; David I Rosenthal; Xiaorong Ronald Zhu; Steven J Frank
Journal:  Int J Part Ther       Date:  2021-06-25

4.  Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers.

Authors:  Robert H Press; Richard L Bakst; Sonam Sharma; Rafi Kabarriti; Madhur K Garg; Brian Yeh; Daphna Y Gelbum; Shaakir Hasan; J Isabelle Choi; Chris A Barker; Arpit M Chhabra; Charles B Simone; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.